Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes

January 29, 2009 updated by: Solvay Pharmaceuticals

A Multi-Center, Double-Blind, Randomized Study Comparing the Efficacy of Combination Therapy of Eprosartan Respectively Ramipril With Low-Dose Hydrochlorothiazide and Moxonidine on Blood Pressure Levels in Patients With Hypertension and Associated Diabetes Mellitus Type 2

This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment

440

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Calgary, Canada
        • Site 26
      • Montreal, Canada
        • Site 27
      • Quebec, Canada
        • Site 30
      • Thornhill, Canada
        • Site 31
      • Vancouver, Canada
        • Site 28
      • Winnipeg, Canada
        • Site 29
      • Holbaek, Denmark
        • Site 39
      • Roskilde, Denmark
        • Site 38
      • Viborg, Denmark
        • Site 40
      • Anzin, France
        • Site 4
      • Blois, France
        • Site 3
      • Chemellier, France
        • Site 10
      • Cholet, France
        • Site 11
      • Cholet, France
        • Site 15
      • Cholet, France
        • Site 16
      • La Jubaudiere, France
        • Site 14
      • Le Mesnil-en-Vallee, France
        • Site 13
      • Murs-Erigne, France
        • Site 7
      • Saumur, France
        • Site 9
      • Segre, France
        • Site 8
      • St Pierre Montlim, France
        • Site 12
      • Thouars, France
        • Site 6
      • Tours, France
        • Site 2
      • Vieux Conde, France
        • Site 5
      • Bad Muenster, Germany
        • Site 20
      • Floersheim, Germany
        • Site 22
      • Kirweiler, Germany
        • Site 19
      • Lambrecht, Germany
        • Site 21
      • Lindau, Germany
        • Site 25
      • Lueneburg, Germany
        • Site 18
      • Lutherstadt, Germany
        • Site 24
      • Riesa, Germany
        • Site 17
      • Waldbrunn, Germany
        • Site 23
      • Bologna, Italy
        • Site 62
      • Napoli, Italy
        • Site 60
      • Padova, Italy
        • Site 58
      • Palermo, Italy
        • Site 59
      • Pavia, Italy
        • Site 63
      • Pisa, Italy
        • Site 61
      • Torino, Italy
        • Site 64
      • Alesund, Norway
        • Site 43
      • Bergen, Norway
        • Site 42
      • Horten, Norway
        • Site 44
      • Skedsmokorset, Norway
        • Site 41
      • Badajoz, Spain
        • Site 55
      • Badalona, Spain
        • Site 51
      • Barcelona, Spain
        • Site 56
      • Barcelona, Spain
        • Site 57
      • Ciudad Real, Spain
        • Site 54
      • Granada, Spain
        • Site 53
      • Madrid, Spain
        • Site 52
      • Angelholm, Sweden
        • Site 48
      • Goteburg, Sweden
        • Site 47
      • Helsingborg, Sweden
        • Site 46
      • Kristianstat, Sweden
        • Site 45
      • Malmo, Sweden
        • Site 50
      • Stockholm, Sweden
        • Site 49
      • Aberdeen, United Kingdom
        • Site 33
      • Bath, United Kingdom
        • Site 36
      • Liverpool, United Kingdom
        • Site 37
      • Manchester, United Kingdom
        • Site 34
      • Oldham, United Kingdom
        • Site 32
      • Rugby, United Kingdom
        • Site 35

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • essential hypertension,
  • diabetes type 2

Exclusion Criteria:

  • severe cardiovascular disease,
  • grade 3 hypertension,
  • secondary hypertension,
  • abnormal liver enzymes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Blood pressure reduction

Secondary Outcome Measures

Outcome Measure
Comparison of responder rates

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2004

Study Registration Dates

First Submitted

September 8, 2005

First Submitted That Met QC Criteria

September 8, 2005

First Posted (Estimate)

September 12, 2005

Study Record Updates

Last Update Posted (Estimate)

January 30, 2009

Last Update Submitted That Met QC Criteria

January 29, 2009

Last Verified

January 1, 2009

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on eprosartan/HCTZ

3
Subscribe